Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

2.3K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
2.3K
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

1.5K
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
1.5K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

990
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
990
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flexible Data Integration for Genomics-Driven Decision Support in Rare Genetic Epilepsy.

Studies in health technology and informatics·2026
Same author

Examining aggressive behavior in patients with epilepsy under treatment with Levetiracetam, Brivaracetam and Perampanel: a comparison to healthy controls.

Frontiers in behavioral neuroscience·2026
Same author

A multicenter, video-EEG-based validation of a multimodal wearable device for focal seizure detection in adults: The SeizeIT2 study.

Epilepsia open·2026
Same author

Headache comorbidity in epilepsy and functional/dissociative seizures: an exploratory cross-sectional study in a tertiary epilepsy center.

Frontiers in neurology·2026
Same author

Antineuronal antibody titres in autoimmune encephalitis: clinical implications for diagnosis and long-term immunotherapy.

Frontiers in immunology·2026
Same author

Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: May 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Cenobamate: real-world data from a retrospective multicenter study.

Stephan Lauxmann1, David Heuer2, Jan Heckelmann3

  • 1Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. stephan.lauxmann@uni-tuebingen.de.

Journal of Neurology
|July 2, 2024
PubMed
Summary

Cenobamate (CNB) is an effective anti-seizure medication for severe drug-resistant epilepsy, showing significant response rates and good tolerability in a real-world cohort. Treatment changes in concomitant anti-seizure medications were also observed.

Keywords:
Adverse drug reactionsAnti-seizure medicationCenobamateDrug-resistant epilepsy

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.6K

Related Experiment Videos

Last Updated: May 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.4K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.6K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Cenobamate (CNB) is an established anti-seizure medication (ASM) for drug-resistant focal epilepsy.
  • Real-world data on CNB across diverse epilepsy syndromes are limited.

Purpose of the Study:

  • To evaluate the efficacy and safety of cenobamate (CNB) in a broad spectrum of epilepsy syndromes.
  • To analyze changes in concomitant anti-seizure medications (ASMs) during CNB treatment.

Main Methods:

  • Retrospective observational study of 116 patients treated with CNB in two German tertiary referral centers.
  • Follow-up data analyzed up to 27 months, assessing treatment response, seizure freedom, dosage, retention, adverse drug reactions (ADRs), and concomitant ASM changes.

Main Results:

  • 50% of patients responded to CNB at 6 months, with sustained response at 12 and 18 months.
  • Seizure freedom was achieved in 18.4% at 6 months.
  • CNB was generally well-tolerated, with ADRs leading to discontinuation in 7.7% of patients.

Conclusions:

  • Cenobamate (CNB) demonstrates high efficacy and tolerability in severe drug-resistant epilepsy across various syndromes.
  • CNB represents a valuable treatment option beyond focal epilepsy.